Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the maximum safe dose of Ra-223 in combination
with fractionated (split doses) docetaxel when given to subjects and to determine the best
administering dose. The study will look at side effects that may happen while taking the
combination treatment. A total of approximately 18 subjects will take part in the dose
escalation part of the study and an additional 25 subjects will participate in the expansion
cohort. This study will be conducted across four centers in the United States.
Phase:
Phase 1
Details
Lead Sponsor:
Tufts Medical Center
Collaborators:
Bayer Henry Ford Hospital Lahey Clinic Ohio State University Comprehensive Cancer Center